Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 1;14:142-157.
doi: 10.1016/j.omtn.2018.11.007. Epub 2018 Nov 20.

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics

Affiliations
Free PMC article
Review

Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics

Bao T Le et al. Mol Ther Nucleic Acids. .
Free PMC article

Abstract

Cancer is one of the leading causes of death worldwide, and conventional cancer therapies such as surgery, chemotherapy, and radiotherapy do not address the underlying molecular pathologies, leading to inadequate treatment and tumor recurrence. Angiogenic factors, such as EGF, PDGF, bFGF, TGF-β, TGF-α, VEGF, endoglin, and angiopoietins, play important roles in regulating tumor development and metastasis, and they serve as potential targets for developing cancer therapeutics. Nucleic acid-based therapeutic strategies have received significant attention in the last two decades, and antisense oligonucleotide-mediated intervention is a prominent therapeutic approach for targeted manipulation of gene expression. Clinical benefits of antisense oligonucleotides have been recognized by the U.S. Food and Drug Administration, with full or conditional approval of Vitravene, Kynamro, Exondys51, and Spinraza. Herein we review the scope of antisense oligonucleotides that target angiogenic factors toward tackling solid cancers.

Keywords: angiogenesis; antisense; antisense oligonucleotides; cancer; modified oligonucleotides; nucleic acids.

Figures

Figure 1
Figure 1
Antisense Oligonucleotide Mechanisms to Alter Gene Expression Different colors in pre-mRNA structure indicate introns and exons.
Figure 2
Figure 2
Examples of Prominent Chemically Modified Nucleotides
Figure 3
Figure 3
Design of Gapmer and Mixmer AO Constructs Green blocks: modified nucleotides; yellow blocks: normal nucleotides.
Figure 4
Figure 4
Discovery Timeline of Angiogenic Factors

Similar articles

See all similar articles

Cited by 3 articles

References

    1. Dias N., Stein C.A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 2002;1:347–355. - PubMed
    1. Agrawal S., Iyer R.P. Perspectives in antisense therapeutics. Pharmacol. Ther. 1997;76:151–160. - PubMed
    1. Sharma H.W., Narayanan R. The therapeutic potential of antisense oligonucleotides. BioEssays. 1995;17:1055–1063. - PubMed
    1. Lundin K.E., Gissberg O., Smith C.I.E. Oligonucleotide Therapies: The Past and the Present. Hum. Gene Ther. 2015;26:475–485. - PMC - PubMed
    1. McClorey G., Wood M.J. An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies. Curr. Opin. Pharmacol. 2015;24:52–58. - PubMed

LinkOut - more resources

Feedback